José Alcamí Pertejo-rekin lankidetzan egindako argitalpenak (10)

2023

  1. Persistent Immunity against SARS-CoV-2 in Individuals with Oncohematological Diseases Who Underwent Autologous or Allogeneic Stem Cell Transplantation after Vaccination

    Cancers, Vol. 15, Núm. 8

2022

  1. Early Cellular and Humoral Responses Developed in Oncohematological Patients after Vaccination with One Dose against COVID-19

    Journal of Clinical Medicine, Vol. 11, Núm. 10

  2. Strong Cellular Immune Response, but Not Humoral, against SARS-CoV-2 in Oncohematological Patients with Autologous Stem Cell Transplantation after Natural Infection

    Journal of Clinical Medicine, Vol. 11, Núm. 8

  3. Strong Humoral but Not Cellular Immune Responses against SARS-CoV-2 in Individuals with Oncohematological Disease Who Were Treated with Rituximab before Receiving a Vaccine Booster

    Cancers, Vol. 14, Núm. 22

2021

  1. Identification of immunological parameters as predictive biomarkers of relapse in patients with chronic myeloid leukemia on treatment-free remission

    Journal of Clinical Medicine, Vol. 10, Núm. 1, pp. 1-21

  2. Impaired Antibody-Dependent Cellular Cytotoxicity in a Spanish Cohort of Patients With COVID-19 Admitted to the ICU

    Frontiers in Immunology, Vol. 12

  3. Impaired Cytotoxic Response in PBMCs From Patients With COVID-19 Admitted to the ICU: Biomarkers to Predict Disease Severity

    Frontiers in Immunology, Vol. 12

  4. Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy

    Biochemical Pharmacology, Vol. 192

2020

  1. Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection

    Biochemical Pharmacology, Vol. 182

2018

  1. Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors

    Biochemical Pharmacology, Vol. 156, pp. 248-264